Paolo Pochettino

  • Citations Per Year
Learn More
This phase II study was designed in order to evaluate efficacy and safety of the combination of vinorelbine (VNB), fluorouracil (FU) and leucovorin (LV) in patients with metastatic breast carcinoma (MBC) previously treated with anthracyclines and taxanes. From 12/2003 to 12/2007, 51 women (median age 59) were treated. Performance status (PS) (ECOG) was 0–2(More)
10086 Background: Neoadjuvant chemotherapy (NACT) has a well established role in multidisciplinary treatment of soft tissue sarcomas (STS). Unfortunately no sure predictive factors have been identified in order to screen those patients who are going to benefit from NACT. Topoisomerase IIα (topo IIα) is a positive target for anthracyclines. Bcl-2 is a(More)
9551 Background: Sarcoma are rare tumors, with an incidence <1% of all neoplasms. Very few data are available on the clinical and psychological needs of the pts in terminal phase of these diseases. In terminal phase the goal is no more cure or prolongation of life, but the control of symptoms related to the disease progression. METHODS As a specialized(More)
e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy. METHODS We reviewed our experience from 1980 and 2008 including 31 patients (pts). Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%),(More)
9035 Background. Results of CT in MSTS remain disappointing. Only 3 agents are active (Adriamycin, Ifosfamide, Deticene) with RR of 16-25% as single agent and 20-40% in poliCT. The 2nd line is more frustrating. The same drugs at different doses or schedules therapy offer 10-15% objective responses, TTP of 3-4 months and MS of 10-12 months. HDI (12-16 g/m2)(More)
BACKGROUND Irinotecan (IRI) is a topoisomerase I inhibitor active as first- or second-line chemotherapy in advanced colorectal cancer (ACRC). Its combination with fluorouracil (FU) increases the response rate and prolongs survival. In order to identify a new effective and less toxic schedule of administration, we planned this phase II study with weekly IRI(More)
  • 1